IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against CTI BioPharma Corp. and Strongly Encourages Investors to Contact the Firm

Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by CTI BioPharma Corp. (“CTI” or the “Company”) (Nasdaq: CTIC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired CTI shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

On February 8, 2016, the Company announced that it had been notified by the U.S. Food and Drug Administration (FDA) that the FDA had placed a partial hold on clinical studies of CTI's main product, pacritinib. When this news reached the investing public, shares dropped nearly 60%.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208006316/en/